第1屆
Point-of-Care Testing
-重點照護檢驗討論會-
分子診斷的實用化
2月19日∼20日

隨著開發期間的縮短和經費的節減，提高了臨床試驗效率化的必要性，為使患者階層化而利用重點照護檢驗的情況增加。此討論會中採用因應重點照護檢驗診斷的技術和傾向，檢討新藥開發領域各種用途之適合性，並表明對診斷服務的服務提供商和製藥公司的商機。此外，亦表示引進診斷（companion）的問題和重點照護檢驗被視為有效工具的理由等。

Who Should Attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Diagnostics, Pathology, Infectious Diseases, R&D, Product Development, and Biotechnology.

Topics will include, but are not limited to:

• Technologies and trends in point-of-care diagnostics
• Deciding which companion diagnostic test to use
• Implementing companion diagnostics
• Partnering with a point-of-care diagnostic developer
• Deciding on criteria for selecting a POC device or provider
• Economics of the POC model for pharma
• Infrastructure needed to make POC work in pharma
• When in the drug development cycle is the right time to bring in a companion diagnostic?
• Who should own the test?
• Who should develop it?
• Can central labs obviate the need for POC in clinical trials?
• Which POC tests are ready for market?

The deadline for submission is July 29, 2011.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.